secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0000950170-25-019862
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M
--------------------------------------------------------------------------------

- Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.
- Net loss $11.6M ($0.44 loss per share) vs $7.1M loss in Q4 2023.
- FY2025 revenue guidance $100-106M (55-65% growth); expects GAAP profitability in Q4 2025.
- Amended OrbiMed credit agreement; adjusted revenue covenants for 2025-2026; issued warrants for 145,180 shares at $0.01/share.
- FDA clearances: Cohealyx (Dec 2024) and RECELL GO mini (Dec 2024); full Cohealyx launch by April 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025019862/0000950170-25-019862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025019862/rcel-20250213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-019862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer